HOUSTON--(BUSINESS WIRE)--ApoCell Inc. has been engaged by Pfizer, Inc. to support a Phase 1 clinical trial being conducted in three sites in the U.S. and abroad. ApoCell will use its target expression profile (TEP™) technology along with immunohistochemistry to generate data to select those patients most likely to benefit from the drug and will then process patient samples to quantify the pharmacodynamic activity of the new drug.
